Foghorn Therapeutics shares are trading higher after Evercore ISI Group initiated coverage on the stock with an Outperform rating and announced a $20 price target.
Portfolio Pulse from Benzinga Newsdesk
Foghorn Therapeutics shares rose following Evercore ISI Group's initiation of coverage with an Outperform rating and a $20 price target.
August 19, 2024 | 2:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Foghorn Therapeutics shares increased after Evercore ISI Group initiated coverage with an Outperform rating and set a $20 price target.
The initiation of coverage by a reputable firm like Evercore ISI Group with an Outperform rating and a specific price target of $20 is likely to boost investor confidence and drive short-term stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100